Sanofi, which markets the two primary treatments for Pompe disease, was trying to add a third one by licensing rights to a Maze Therapeutics drug candidate with a different therapeutic approach. A Federal Trade Commission complaint alleges the deal amounts to a monopoly player taking out its competition.
Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant’s $28 billion Horizon Therapeutics acquisition. As part of the settlement, Amgen agrees not to “bundle” its products with Horizon’s drugs in negotiations with health plans.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
A class-action lawsuit, filed by six North Carolina residents, alleges that HCA Healthcare bought Mission Health to gain monopolistic control in the Western part of the state, enabling it to drive up prices while lowering the quality of care.